Resmetirom for treatment of MASH.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38848671.
- Also identified by DOI 10.1016/j.cell.2024.05.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Liver Cirrhosis
- Pyridazines
- Uracil